Etanercept- @entity1499 combination therapy initiators have greater adherence and persistence than triple therapy initiators with XXXX .

@entity1 @entity309 @entity6822 @entity6383 @entity1499 @entity3378
OBJECTIVE: To estimate adherence and persistence with etanercept plus @entity1499 (ETN- @entity6822 ) combination therapy and @entity6822 , @entity6383 , and @entity3378 triple therapy at 1 year following treatment initiation in adults with @entity309 ( @entity309 ). METHODS: This retrospective analysis used data from the Truven Health MarketScan   Commercial and Medicare Supplemental databases from January 2009 to July 2013. Adherence was defined as having Percentage of Days Covered   >   80% for all drugs within each regimen. Persistence was defined as no   >   45-day treatment gap with any drug and no addition or switch to other disease-modifying antirheumatic drugs. Multiple logistic regression models were employed in the analyses to control for potential confounders. RESULTS: A total of 3,724 ETN- @entity6822 @entity1 and 818 triple therapy @entity1 were eligible. At 1 year, 27.9% on ETN- @entity6822 and 18.2% on triple therapy were adherent to all agents in their regimen (P   <   0.0001) and 29.4% on ETN- @entity6822 and 23.2% on triple therapy were persistent (P   <   0.001). After adjusting for confounders, ETN- @entity6822 @entity1 had significantly greater odds of being adherent (odds ratio [OR] 1.79; 95% confidence interval [CI] 1.47, 2.17) and persistent (OR 1.45; 95% CI 1.20, 1.72) compared with @entity1 on triple therapy. CONCLUSION: @entity1 with @entity309 initiating treatment with ETN- @entity6822 combination therapy demonstrated greater adherence and persistence at 1 year than @entity1 initiating triple therapy. This article is protected by copyright. All rights reserved.
